• Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Glu507Gln (c.1519G>C); Zygosity=Unspecified (PubMed=24367658).
  
• Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg557Pro (c.1670G>C); Zygosity=Unspecified (PubMed=24367658).
  
• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
  

PubMed=19802009; DOI=10.1038/onc.2009.315
Askham J.M., Platt F.M., Chambers P.A., Snowden H., Taylor C.F., Knowles M.A.
AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
Oncogene 29:150-155(2010)

PubMed=24367658; DOI=10.1371/journal.pone.0084411; PMCID=PMC3867501
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)